• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

October 7, 2019
Company Drug/Device Medical Condition Status
Themis Bioscience and ZIKAVAX Second-generation Zika vaccine Zika virus Phase 1 study initiated enrolling 48 healthy subjects
Noveome Biotherapeutics, Inc. ST266 intraocular hypertension Phase 1 trial initiated enrolling subjects at the University of Pennsylvania who have been diagnosed with intraocular hypertension who have not yet developed optic nerve damage
Clover Biopharmaceuticals SCB-313 malignant ascites Phase 1 trial initiated enrolling subjects in China
Oncternal Cirmtuzumab in combination with Ibrutinib Mantel cell lymphoma (MCL) Phase 1b expansion cohort trial initiated to confirm the RDR
AVEO Oncology AstraZeneca Tivozanib (FOTIVDA) and Durvalumab (IMFINZI) hepatocellular carcinoma (HCC) Phase 1b/2 trial initiated enrolling 50 subjects with hepatocellular carcinoma (HCC) who have not received prior systemic therapy
Checkmate Pharmaceuticals Inc. CMP-001 in combination with BAVENCIO (avelumab), utomilumab (4-1BB agonist) and PF-04518600 (OX40 agonist) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 1b/2 trial initiated enrolling 60 subjects with Squamous Cell Cancer of the Head and Neck (SCCHN)
Adrenomed Adrecizumab septic shock Phase 2 trial initiated enrolling 300 subjects with early septic shock and elevated blood levels of Adrenomedullin
Oncopeptides AB melflufen with dexamethasone relapsed/refractory multiple myeloma (RRMM) Phase 2 trial initiated enrolling 150 subjects
North Sea Therapeutics Icosabutate NASH (Non-alcoholic Steatohepatitis) Phase 2b trial initiated enrolling 264 subjects
Immutep eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA(R) (or pembrolizumab, an anti-PD-1 therapy) Non-small cell lung cancer (NSCLC) Phase 2 expansion cohort trial initiated enrolling 19 subjects with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line in 13 study centers across the U.S., Europe and Australia
Cortexyme COR388 Alzheimer’s Disease Phase 2/3 trial initiated enrolling 570 subjects in U.S. and Europe
Incyte ruxolitinib cream vitiligo Phase 3 trial initiated enrolling 300 adolescent and adult subjects ages 12 and older who have been diagnosed with non-segmental vitiligo
Galmed Pharmaceuticals Ltd. SCD1 modulator Aramchol nonalcoholic steatohepatitis ("NASH") and fibrosis Phase 3/4 trial initiated enrolling 2,000 subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes at 185 sites in the U.S., Europe, Latin America and Asia.
Luminex Corporation ARIES MRSA Assay methicillin-resistant Staphylococcus aureus (MRSA) 510 (k) clearance granted by the FDA
Exogenesis Corporation Exogenesis Hernia Mesh soft tissue repair, abdominal wall hernias and abdominal wall deficiencies 510 (k) clearance granted by the FDA
(LAS) Laser Associated Sciences FlowMet-R peripheral artery disease (PAD) 510 (k) clearance granted by the FDA
Janssen Pharmaceuticals INVOKANA (canagliflozin) Heart failure in patients with type 2 diabetes (T2D) and DKD Approval granted by the FDA
Janssen Pharmaceuticals Darzalex multiple myeloma Approval granted by the FDA
AbbVie MAVYRET (glecaprevir/pibrentasvir) naïve chronic hepatitis C (HCV) with
cirrhosis or with compensated cirrhosis
Approval granted by the FDA
Genentech Rituxan (rituximab) injection granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids (steroid hormones) Approval granted by the FDA

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing